Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

CrossAmerica Partners (CAPL) Accumulated Depreciation & Amortization (2016 - 2026)

CrossAmerica Partners filings provide 15 years of Accumulated Depreciation & Amortization readings, the most recent being $413.0 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 1.56% to $413.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $413.0 million, a 1.56% increase, with the full-year FY2025 number at $413.0 million, up 1.56% from a year prior.
  • Accumulated Depreciation & Amortization hit $413.0 million in Q4 2025 for CrossAmerica Partners, up from $407.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $413.0 million in Q4 2025 to a low of -$225000.0 in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $343.5 million (2023), compared with a mean of $322.3 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 100.1% in 2022 and later surged 143982.22% in 2023.
  • CrossAmerica Partners' Accumulated Depreciation & Amortization stood at $262.0 million in 2021, then grew by 19.17% to $312.2 million in 2022, then rose by 16.57% to $363.9 million in 2023, then grew by 11.74% to $406.7 million in 2024, then grew by 1.56% to $413.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $413.0 million (Q4 2025), $407.5 million (Q3 2025), and $399.7 million (Q2 2025) per Business Quant data.